Plant Name: Viburnum davidii
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.185E-08 | 2.346E-05 | CA1, CA12, CA2, CA3, CA5A, CA6, CA7, CA9, NR1H4, PTPN1, TP53 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 9.105E-07 | 1.322E-03 | CA2, CA7, HIF1A, HTT, NR1H4, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.523E-06 | 5.073E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 6.523E-06 | 5.073E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 6.523E-06 | 5.073E-03 | GPBAR1, NR1H4 |
| BP | GO:0065007; biological regulation | GO:0050790; regulation of catalytic activity | 1.006E-05 | 7.301E-03 | CASP1, CASP7, CDC25B, GLA, HIF1A, HTT, NFKB1, PLA2G1B, PTPN1, PTPN2, TP53, TSHR, XDH |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 1.303E-05 | 8.601E-03 | PTPN1, PTPN2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.841E-23 | 1.054E-18 | CA1, CA12, CA14, CA2, CA3, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.674E-18 | 5.719E-14 | CA1, CA12, CA14, CA2, CA3, CA5A, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.634E-16 | 1.147E-12 | CA1, CA12, CA2, CA3, CA5A, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.716E-22 | 1.871E-20 | CA12; CA1; CA3; CA2; CA5A; CA7; CA6; CA9; CA14 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 9.765E-06 | 5.322E-04 | PLA2G1B; ALOX15; CYP2C19 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 6.835E-05 | 2.483E-03 | CASP7; CASP1; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 9.787E-05 | 2.667E-03 | PLA2G1B; ALOX15; CYP2C19 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.725E-04 | 3.761E-03 | CASP7; CASP1; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.074E-03 | 1.672E-02 | CASP7; TP53; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 3.186E-03 | 3.270E-02 | POLB; TP53; NFKB1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 8.611E-04 | 1.564E-02 | AKR1B10; GLA |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 2.477E-03 | 3.270E-02 | CASP1; TP53 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 3.300E-03 | 3.270E-02 | AKR1B10; GLA |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 3.084E-03 | 3.270E-02 | CASP1; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 4.111E-03 | 3.296E-02 | TP53; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 5.859E-03 | 3.643E-02 | TP53; NFKB1; CDC25B |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.234E-03 | 3.296E-02 | TP53; HIF1A |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 6.052E-03 | 3.643E-02 | POLB; TP53; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 5.006E-03 | 3.410E-02 | TP53; NFKB1 |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 3.871E-03 | 3.296E-02 | CASP1; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.742E-03 | 3.410E-02 | CA2; NR1H4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 7.353E-03 | 3.643E-02 | TP53; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 6.881E-03 | 3.643E-02 | TP53; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 8.903E-03 | 3.882E-02 | TP53; NFKB1; CDC25B |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 8.170E-03 | 3.864E-02 | TP53; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 6.881E-03 | 3.643E-02 | CASP1; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 9.740E-03 | 4.083E-02 | HIF1A; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.105E-02 | 4.298E-02 | CASP7; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.086E-02 | 4.298E-02 | PTPN1; NFKB1 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 8.508E-03 | 3.864E-02 | CA2; PLA2G1B |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.143E-02 | 4.298E-02 | ALOX15; CYP2C19 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.263E-02 | 4.442E-02 | TP53; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.304E-02 | 4.442E-02 | TP53; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.304E-02 | 4.442E-02 | TP53; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.388E-02 | 4.584E-02 | TP53; CDC25B |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 7.230E-03 | 3.643E-02 | XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; CA1; CA9; NFKB1; CDC25B |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; NFKB1 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| NA: NA | Edema | NA | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; PLA2G1B |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |